Anti-angiogenic Agents in Ovarian Cancer: Dawn of a New Era?

[1]  R. Wenham,et al.  Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  B. Karlan,et al.  Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Oza,et al.  Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Cohn,et al.  At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Burger,et al.  Overview of anti-angiogenic agents in development for ovarian cancer. , 2011, Gynecologic oncology.

[7]  M. Hensley.  Big costs for little gain in ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  U. Matulonis.  Bevacizumab and its use in epithelial ovarian cancer. , 2011, Future oncology.

[9]  E. Eisenhauer,et al.  A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  A. Oza,et al.  ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC) , 2010 .

[11]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[12]  I. Brandslund,et al.  The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. , 2010, Gynecologic oncology.

[13]  B. Monk,et al.  Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Stepanski,et al.  A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. , 2010 .

[15]  J. Hainsworth,et al.  A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer. , 2010 .

[16]  Percy Ivy,et al.  Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Jobo,et al.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[18]  G. Jayson,et al.  A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Marrero,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  R. Burger,et al.  Relationship between angiogenic markers and clinicopathologic factors/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC) , 2008 .

[21]  A. Oza,et al.  A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial , 2008 .

[22]  M. Roberts,et al.  What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? , 2008, Medical care.

[23]  A. Sood,et al.  Markers of Angiogenesis in Ovarian Cancer , 2007, Disease markers.

[24]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Howard Mackey,et al.  Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Schilder,et al.  Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Rettenmaier,et al.  A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer , 2006, International Journal of Gynecologic Cancer.

[28]  A. Oza,et al.  VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study , 2007 .

[29]  A. Iasonos,et al.  A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer , 2007 .

[30]  C. Stringer,et al.  Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study , 2007 .

[31]  R. Zeillinger,et al.  Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. , 2006, Gynecologic oncology.

[32]  Gianni Tognoni,et al.  Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials , 2006, JAMA.

[33]  M. Geller,et al.  Angiogenesis in normal and neoplastic ovaries , 2005, Angiogenesis.

[34]  S. Kassim,et al.  Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. , 2004, Clinical biochemistry.

[35]  Jinshun Zhao,et al.  Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. , 2004, Anticancer research.

[36]  Anil K Sood,et al.  Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  R. Dodge,et al.  The prognostic significance of angiogenesis in epithelial ovarian carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  D. Sherer,et al.  Angiogenesis in primary and metastatic epithelial ovarian carcinoma. , 1997, American journal of obstetrics and gynecology.

[39]  S. Steinberg,et al.  Tumor angiogenesis in advanced stage ovarian carcinoma. , 1995, The American journal of pathology.

[40]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.

[41]  A. Secord,et al.  Antiangiogenic therapies in epithelial ovarian cancer. , 2011, Cancer control : journal of the Moffitt Cancer Center.

[42]  K. Markou,et al.  National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010. , 2011 .

[43]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[44]  S. Cannistra,et al.  Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  S. Groshen,et al.  Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  N. Yang,et al.  Animal Model Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma , 2002 .